The effects of different prebiotics and oxygen scavengers on making the process of xanthan gum and chitosan (XC) Bifidobacterium bifidum BB01 microcapsules were studied by single factor experiment and Plackett-Burman screening test, ascorbic acid, sodium erythorbate and xylo-oligosaccharide had significant effects. Based on the previous studies, the process XC B. Bifidum BB01 microcapsules were further optimized by Box-Behnken model in this study. Response surface analysis showed that the best additive amoumt of ascorbic acid, sodium erythorbate and xylo-oligosaccharide were 3.0%, 2.36% and 4.99%, respectively. The viable counts of B. Bifidum BB01 microcapsules reached to 1.52×10 10 CFU/g from 1.25×10 10 CFU/g, the encapsulation yield reached to 94.88% from 90% under the optimum conditions. It provided the research foundation for the afterward production and exploration of the process XC B. Bifidum BB01 microcapsules.
INTRODUCTION
Probiotics have been viewed as food supplements traditionally. However, in recent years, probiotics have been increasingly prescribed as nutraceuticals in light of their therapeutic effects, which range from alleviating symptoms of lactose malabsorption and irritable bowel syndromes to suppressing colon cancer and enhancing resistance to gut infections (Kailasapathy & Chin, 2000; Sanders et al., 2013) . Probiotics have been primarily selected from the genera Lactobacillus and Bifidobacterium, which are part of lactic acid bacteria (LAB) group. Some of the usual Bifidobacterium microorganism are Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus and Lactobacillus GG (Timmerman et al., 2004) . Bifidobacterium is a very crucial type of intestinal probiotics, which has important physiological and healthy functions on the human body (Wean et al., 2014) . It can be employed to inhibit the growth of saprophytic bacteria, lower cholesterol and synthetic vitamins and promote calcium absorption and other functions. Some researchers have suggested that the viable counts of intestinal B. Bifidum can reflect a person's health status in a way. Probiotics provide their health benefits to maintain health by inhibiting harmful microbe growths, that also can promote gut microflora and stimulate the host's immune response (Figueroa-Gonzalez et al., 2011) . The probiotics must maintain viable counts to provide these benefits, however after the probiotics reach the small intestine, the high concentrations of bile solutions can cause a substantial reduction in the activity of probiotics (Huiyi et al., 2013; Wean et al., 2014) , which are difficult to achieve in their healthful effects. Therefore, the increase of viable counts in probiotic products and the improvement of the acid resistance and bile tolerance for the bacterial cells have becoming urgent problems needed to be solved. One effective method to protect probiotic cells from the stresses encountered during processing and gastrointestinal transit is by microencapsulation of probiotic cells into polysaccharide carrier matrices such as Sodium Alginate, Xanthan Gum, Gelatin, Carrageenan, Chitosan, Starch, Proteins. Microencapsulation has been found to enhance the cell survival rate upon freeze drying (Heidebach et al., 2010), meanwhile protect the cells from the acidic environment of the stomach and facilitating the cell release gradually in the intestinal sections of the gut Later (Cook et al., 2011; Guerin et al., 2003) . Microencapsulation is a promising technique. Protection of probiotics by microencapsulation in hydrocolloid capsules prepared has been investigated, which method including by extrusion, emulsion, or atomized micro particles (Doleyres & Lacroix, 2005) . Microencapsulation by spray drying has been used prosperously in the food industry for several decades (Gouin, 2004) . Encapsulation of brewing yeast in alginate/chitosan matrix has been applied in beer fermentation (Naydenova et al., 2014) . The encapsulation material was changed based on the study of probiotic B. Bifidum BB01 microencapsulation, the probiotics B. Bifidum BB01 was embedding by the combination of xanthan gum and chitosan. Xanthan gum and chitosan are natural biological macromolecules with good biocompatibility with non-toxic side effects (Graziela et al., 2011) . Chitosan is soluble in acidic aqueous solution and its amino group is positively charged in acidic solution. The anionic polysaccharide xanthan gum is co-gel with chitosan through polyelectrolyte complexing, which can be used as microcapsule wall material. Oxygen scavenger can eliminate the oxygen for the strain B. Bifidum BB01, prebiotics as B. Bifidum BB01 growth promoting factor, promote the growth of B. Bifidum BB01 to a certain extent (De et al., 2012) . The effects of different prebiotics and oxygen scavengers on viable counts and encapsulation yield of making the process of XC Bifidobacterium bifidum BB01 microcapsules were performed by single factor experiments and Plackett-Burman designed experiment. ascorbic acid, sodium erythorbate and xylo-oligosaccharide were selected as main factors, which had positive effects on viable counts and encapsulation yield. According to the results of the steepest ascent experiment, 3.0%, 2.4%, 5.0% were set as the centers of Box-Behnken design (data unpublished). The aim of this study is to optimize the levels of the significant factors (ascorbic acid, sodium erythorbate and xylo-oligosaccharide) for the viable counts and encapsulation yield of making the process of XC Bifidobacterium bifidum BB01 microcapsules by using Box-Behnken design based on the previous study.
MATERIAL AND METHODS
Strain, media and previous preparation: Starter bacteria of B. Bifidum BB01 was obtained from the School of Food and Biological Engineering, Shaanxi University of Science and Technology. They were inoculated in MRS-broth and cultured three generations at 37°C for 24 hours, the cells were collected by centrifugation with 4000 rpm for 10 min at 4°C, and then the cell was washed twice and adjusted viable counts to 10 11 CFU/ mL by suspending 0.1 ml into 0.9 g/mL sterilized saline at last. MRS-broth and MRS-agar (Hope Bio-Technogy Co., Ltd. Qingdao) were used to culture and count B. Bifidum BB01. Xanthan (Zhongxuan biological chemistry Co., Ltd., Shandong, China) was dissolved in deionized water (DIW) to the concentration of 0.68% (w/v), which weight of molecular was 1.02 million, then this solution was sterilized for 10min at 110 ℃ . Chitosan (Xingcheng Biological Co., Ltd., Jiangsu, China), which weight of molecular was 0.37 million, was dissolved into stirring HCL (1 mol/L) solution to the 0.76% (w/v) concentration. Microencapsulation procedure and encapsulation yield: Prebiotics or oxygen scavengers were mixed with the bacterial suspension proportionally that was decentralized in xanthan solution thoroughly. Then the mixture solution was dripped into chitosan solution which placed on the magnetic stirrer. The mixed solution was stirred continuously until the wet capsule was fully formed. The XC (xanthan gum and chitosan) beads loaded with B. Bifidum BB01 was obtained thought the wet capsules were filtered and washed 3 times by sterilized saline water (Shoji et al., 2013) . According to the previous experiment, B. Bifidum BB01 microcapsules were prepared with chitosan 0.87%, pH 4.24, xanthan gum 0.5%, bacteria suspension and xanthan gum ratio of 1: 3.8 (v/v); the ratio of xanthan gum to chitosan was 1: 7.7 (v/v). Measurement of viable counts: Bifidobacteria were counted using a high-layer agar medium. The test sample was diluted 10 times with sterile saline, 1mL different dilutions of Bifidobacterium suspension was injected into the high-level agar medium, incubated at 37℃ for 48-72h, observe the colony growth and counts. Calculate the viable cell number per unit volume of B. Bifidum BB01 microcapsules.
Viable counts were count according to Eq. (1): Vc=N×T (1) where VC represents the viable counts in per milliliter of the original suspension (CFU/mL), N is the average colony number in triplicate anaerobes tubes in the same dilution (CFU). T means dilution times. Measurement of encapsulation yield: 1g microcapsules were dispersed in 10mL of simulated intestinal juice, after being vibrated with 200 rpm for 35 min at 37 °C. The encapsulation yield would be counted according to Eq. (2):
(2) where N1 (CFU/mL) was viable counts of microcapsules after simulated intestinal juice treatment. N0 (CFU/mL) was the viable counts in the cell suspension at the outset. W (g) was the weight of the wet microcapsule. V0 (mL) was the original volume of bacterial suspension used for microcapsule. Box-Behnken Design (BBD) and statistical analysis: The Box-Behnken design under the response surface methodology (RSM) developed by the Design Expert software (Version 8.0.6) was used to further optimized the process of XC B. Bifidum BB01 microcapsules based on the results of single factor and Plackett-Burman experiments. The three significant factors, ascorbic acid (A), sodium erythorbate (B), xylo-oligosaccharide (C) were independent variables, which were studied at three different levels (−1, 0, 1). The actual factors levels were shown in Table 1 . 
RESULTS AND DISCUSSION
Experimental design using BBD of three independent variables including three replicates at the central point is given in Table  2 , showing the experimental and predicted response.
BB01 microcapsules by Response Surface Methodology 
Regression analysis of the data
Design-Expert software was applied for regression analysis and model fitting of experimental data based on the experimental results of Table 2 . The experiment results analysis was performed by Design-Expert software to fit out equations: 
Variance analysis
The adequacy of the model was checked using analysis of variance (ANOVA) which was tested using statistical analysis and the results are shown in Table 3 . The effects of variables were determined by the F-test, and the more obvious effect on the variables with the lower p-value. The R-squared value provided a measure of the variability of the response values that could be explained by the experimental factors and their interactions. The p-value could test the significance of each coefficient and reveal the interaction pattern of independent variables (Mkadmini et al., 2016) , if the p-value less than 0.05, the corresponding variables would be more significance. As shown in Table 3 , the p-value of viable counts (Y1) demonstrates a high significance for regression equation (p = 0.0004 < 0.001), and the p-value of lack of fit was 0.0714 (p > 0.05), which indicates that the model adequately fitted the experimental data and proves the adequacy of the regression model. What's more, the results showed that for three responses, two independent variables including the ascorbic acid (A) , sodium erythorbate (B) and had significant quadratic effects (p<0.05). Table 3 , it could be seen that the effect of ascorbic acid (A) on the encapsulation yield of microcapsules was significant. The A 2 and C 2 were very significant, which demonstrated that the simple linear relationship couldn't be used to explain the relevance of each factor. The p-value of the model was inferior to 0.001, and the lack of fit p-value was superior to 0.05, which showed that the model was available. The regression coefficient R 2 of the obtained equation was 98.43% with a negligible experimental error, showing that the response model could explain that 98.43 % of the variation in the specific activity was explained by the model. The adjusted R 2 (95.59%) also implied statistical significance of the model, which suggested a good relationship between the predictive and the measured value of encapsulation yield with the regression equation. Two-dimensional contour plot could describe the interactions between independent variables (ascorbic acid, sodium erythorbate, xylooligosaccharide) that were significant or not. And the three-dimensional response surface plots were plotted to assess the effect of independent variables on the response value (Zhang et al., 2016) . The viable counts of XC B. Bifidum BB01 microcapsules was investigated when two varieties kept in experimental range and other variety fixed at zero (Figure 1 Elliptical contour plots demonstrated significant interaction between the independent variables (Ghavi, 2015) . For ascorbic acid (A) and sodium erythorbate (B) (Figure 1a) , the contour plot was oval prominently, which showed strong mutual interaction between parameters A and B, (pAB=0.0368) fit well with the results of interaction terms in variance analysis. The same trend was noticed between parameters B and C (Figure 1e) , the mutual interaction between sodium erythorbate (B) and xylo-oligosaccharide (C) was strong, (pBC=0.0072) which indicated the mutual influence between sodium erythorbate and xylo-oligosaccharide was significant. As shown in Figure 2a that the effect of the addition of ascorbic acid (A) and sodium erythorbate (B) on the encapsulation yield of XC B. Bifidum BB01 microcapsules. When the ascorbic acid at a certain level, the encapsulation yield increased with the amount of sodium erythorbate additive increased firstly and then decreased. When the sodium erythorbate at a certain level, the encapsulation yield increased with the amount of ascorbic acid additive increased firstly and then decreased. Vol. XXII (2018), no. 1 As the relationship between ascorbic acid (A) and xylo-oligosaccharide (C) (Figure 2c ), the contour plot was close to be a circle, showing weak mutual interaction between parameters A and C.
Verification of the model
The obtained ternary quadratic regression equation was analyzed by using the Design-Expert software. The optimal values of independent variables and response variable were as follows: the addition of ascorbic acid (A), sodium erythorbate (B) and xylo-oligosaccharide (C) were 3.0%, 2.36% and 4.99%, respectively. Triplicate confirmatory experiments were carried out under these optimal conditions of addition. The average viable counts and encapsulation yield were 1.50±0.12×10
10 CFU/g and 95±0.8%, respectively, which has been significantly improved compared with un-optimized and provides a reference for the follow-up test. The measured values were in agreement with the predicted ones (viable counts was 1.52×10 10 CFU/g and encapsulation yield was 94.88%). The probiotic strains used in foods are usually anaerobic or microaerophilic. Hence, the presence of oxygen in the product may lead to microbial poisoning, death and loss of function (Cruz et al., 2007) . Cui added L-Cysteine which usually were used for the culture of bifidobacteria as an oxygen scavenger in the process of encapsulation of microcapsules, BB01 microcapsules by Response Surface Methodology increasing the viable counts of microcapsule-embedded greatly (Cui et al., 2000) . The oxygen scavenger may promote a more favorable anaerobic environment that has a protective effect on probiotic cells during storage (Shah et al., 2010) . The effects of ascorbic acid and sodium erythorbate on viable counts were mainly due to which can eliminate the stress of remaining oxygen in solution. Probiotics can regulate the intestinal microbiota through selectively fermentable prebiotics that play a beneficial role in the growth of bacteria in the colon (Gibson et The analysis results of the resistance and stability for probiotics to exposed to simulated gastric fluids (SGF) and solid lipid microparticles (SLM) suggested that the addition of prebiotic components during embedding had increase viable counts compared with free probiotic cells which by the study of Okuro et al. (2013) . Chen et al. (2017) found good encapsulation systems XC and XCX in yogurt, which protected probiotic B. Bifidum BB01 effectively during exposure to adverse environment conditions and the single-layer microcapsules XC showed better release profile in SIF. A study by Chen et al. (2014) showed that sodium erythorbate was used in the production process of XC B. Bifidum BB01 microcapsule, the corresponding viable counts and encapsulation yield of microcapsules were 2.9×10 9 CFU/ml, 82%, respectively. The addition of 3.2g/L sodium erythorbate during the fermentation process could effectively reduce the stress caused by oxygen on B. bifidum, and the viable counts in the fermentation broth reached 1.06×10 9 CFU/ml, which was demonstrated by Li et al. (2008) . The results of all above studies were lower than my research. The reason was the synergistic effect of three factors occurred probably in my study, which result to a better performance.
CONCLUSION
According to the results of BBD, three groups of repeated experiments were carried out on the optimized conditions (3.0% ascorbic acid addition, 2.36% addition of sodium erythorbate and 4.99% xylo-oligosaccharide added). The viable counts of XC B. Bifidum BB01 reached to 1.52×10 10 CFU/g from 1.25×10 10 CFU/g and the encapsulation yield reached to 94.88% from 90% under the optimum conditions, which were increased 21.6% and 5.4%, respectively. There was no significant difference between the verification value and the predicted value, which proved the effectiveness of the model. There were few researches on adding probiotics and oxygen scavengers during the process of preparing microcapsules and increase the viable counts of microcapsules was a difficult problem in microcapsule processing simultaneously at present. This research provides the basis for future research on XC B. Bifidum BB01 microcapsule encapsulation technology.
